Production (Stage)
MoonLake Immunotherapeutics
MLTX
$46.88
-$1.95-3.99%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 34.54M | 30.32M | 28.03M | 26.04M | 23.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 170.76M | 143.09M | 108.54M | 78.40M | 61.01M |
| Operating Income | -170.76M | -143.09M | -108.54M | -78.40M | -61.01M |
| Income Before Tax | -147.46M | -120.96M | -82.45M | -58.02M | -45.68M |
| Income Tax Expenses | 364.90K | 281.90K | 285.10K | 221.90K | 153.30K |
| Earnings from Continuing Operations | -147.83 | -121.24 | -82.74 | -58.24 | -45.84 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 2.62M | 2.31M | 1.97M | 3.44M | 5.16M |
| Net Income | -145.21M | -118.93M | -80.77M | -54.80M | -40.68M |
| EBIT | -170.76M | -143.09M | -108.54M | -78.40M | -61.01M |
| EBITDA | -169.02M | -141.40M | -107.79M | -77.68M | -60.32M |
| EPS Basic | -2.30 | -1.89 | -1.29 | -0.90 | -0.75 |
| Normalized Basic EPS | -1.42 | -1.16 | -0.79 | -0.54 | -0.43 |
| EPS Diluted | -2.30 | -1.89 | -1.29 | -0.90 | -0.75 |
| Normalized Diluted EPS | -1.42 | -1.16 | -0.79 | -0.54 | -0.43 |
| Average Basic Shares Outstanding | 252.08M | 251.48M | 248.32M | 238.94M | 219.79M |
| Average Diluted Shares Outstanding | 252.08M | 251.48M | 248.32M | 238.94M | 219.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |